ENGLEWOOD, Colo., Oct. 8, 2018 /PRNewswire/ -- Zynex, Inc. (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announces that it has obtained a U.S. utility patent for its Blood Volume Monitor Device. Thomas Sandgaard, the inventor, has assigned the patent to Zynex's subsidiary, Zynex Monitoring Solutions.
Thomas Sandgaard, CEO said: "I am excited to have obtained patent protection for the core principles of how we detect fluid imbalances such as excessive blood loss during surgery or internal bleeding in recovery. The algorithm which computes multiple vital signs into an easy-to-understand Index is now protected through this patent. This breakthrough technology is unique as there are no other non-invasive devices available that can detect blood loss or internal bleeding.
We believe our non-invasive, easy-to-operate technology will serve a huge unmet need to manage blood volume in hospital and surgical settings, whether it is fluid loss, fluid overload or internal bleeding which is rarely detected until it becomes critical or fatal. We have previously received a strong interest in our Blood Volume Monitor from the US Army when we provided them with a live demonstration of the product that is fully developed and in pilot production. It should be noted, we are still awaiting FDA clearance and European CE marking to fully launch the product into the market.
We believe lives can be saved with this technology as significant complications are avoided during surgery. Fluid management issues can cause organs to malfunction and make recovery more difficult.
We are pushing for getting additional claims patented to strengthen our intellectual property position as well as awaiting the results of our European patent application."
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force our ability to up-list to a larger exchange and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2017 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's website. Contact: Zynex, Inc. (303) 703-4906
Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel
SOURCE Zynex, Inc.